iSpecimen raises $400K in Series D preferred placement as revenue slides
What's the deal? iSpecimen, a biospecimen marketplace operator, raised $400,000 in gross proceeds through a private placement of 500 shares of Series D Convertible Preferred Stock. It signed the securities purchase agreement on November 6, 2026, selling shares at $800 each against a $1,000 stated value. The company plans to use net proceeds for working capital and general corporate needs.
The terms: The preferred stock carries an 8% annual cumulative dividend, payable quarterly in cash or common stock. Holders can convert at the greater of 85% of the prior day's closing price or a $0.1616 floor.
Conversions are capped at 1,157,223 common shares — 19.99% of pre-transaction shares outstanding — until shareholders approve under Nasdaq Rule 5635(d). E.F. Hutton & Co. acted as exclusive placement agent on a reasonable best efforts basis.
Why now? The raise lands amid operational strain. Second-quarter 2026 revenue fell 79% year over year to about $152,000, and iSpecimen has been working to meet Nasdaq's stockholders' equity requirement.
What's the endgame? iSpecimen is trying to broaden beyond its biospecimen marketplace, including a planned $4.5 million acquisition of Foldlab AI assets. That push adds to its capital demands.
Context: The $400,000 placement is modest against recent financings. iSpecimen raised $5.5 million in a Series C placement in December 2025, $2.5 million in a May 2026 private placement, and $5 million in an August public offering.
The signal: This is a small infusion, not a turnaround — and its real impact hinges on the preferred stock's conversion and dilution terms, which the headline figure alone doesn't settle. For a company stacking repeated raises against falling revenue, the pattern matters more than any single round.
Read more: panabee.com
Image credit: U.S. Navy Medicine
